Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIV. (17th September 2021)

• Record Type: Journal Article
• Authors: Castillo-Mancilla, Jose R; Morrow, Mary; Coyle, Ryan P; Coleman, Stacey S; Zheng, Jia-Hua; Ellison, Lucas; Bushman, Lane R; Kiser, Jennifer J; Anderson, Peter L; MaWhinney, Samantha
• Is Part Of: Open forum infectious diseases. Volume 8:Number 9(2021)
• Publication Date: 2021-09-17
• Subjects: low-level viremia -- adherence -- dried blood spots -- tenofovir diphosphate -- antiretroviral therapy; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofab463
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: The drivers of low-level viremia (LLV) between 20 and 200 copies/mL remain unclear. In 1042 person-visits from 497 persons with HIV on tenofovir disoproxil fumarate–containing antiretroviral therapy (ART), the association between LLV and cumulative antiretroviral adherence (quantified using tenofovir diphosphate [TFV-DP] in dried blood spots) was assessed. Lower TFV-DP levels were associated with higher odds of LLV. As TFV-DP (fmol/punch) categories decreased from >1650 to 800–1650; 800–1650 to <800; and >1650 to <800, the adjusted odds ratios for LLV vs HIV VL <20 copies/mL were 2.0 (95% CI, 1.2–3.1), 2.4 (95% CI, 1.1–5.0), and 4.6 (95% CI, 2.2–9.9), respectively. This suggests that adherence could impact LLV.